ClinicalTrials.gg
CompletedNCT01483742Updated Aug 1, 2016

A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

A Phase 2 interventional study of RO5024048 and danoprevir in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 27 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-08-01.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing danoprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. danoprevir · Hepatitis C, Chronic.

Enrollment
9th of 10
43 · median 79
Started
2012
with 1 other
Phase 2
7 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
7 of 10
Hoffmann-La Roche

Among the 10 studies testing danoprevir in Hepatitis C, Chronic, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 5th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 10 studies testing danoprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About danoprevir

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing danoprevir in Hepatitis C, Chronic as a file.
02

Study summary

This open-label, parallel cohort study will evaluate the safety, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients, and with RO5024048 added to the combination treatment in prior null responder patients with chronic hepatitis C genotype 1 or 4 and compensated cirrhosis. All patients will receive danoprevir 100 mg orally twice daily (bid) , ritonavir 100 mg orally bid, Pegasys 180 mcg subcutaneously weekly and ribavirin 1000-1200 mg/kg/day orally. Prior non-responders will receive RO5024048 1000 mg orally bid additionally. Anticipated time on study treatment is 24 weeks.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 18 to 65 years of age inclusive
  • Chronic , genotype 1 or 4
  • Cohort 1: Treatment-naïve for hepatitis C
  • Cohort 2: Prior null responder to treatment with approved doses of pegylated interferon plus ribavirin
  • Liver confirming cirrhosis
  • Compensated cirrhosis ( A)

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women or male partners of women who are pregnant
  • History or presence of decompensated liver disease (ascites, hepatic encephalopathy, hepatocellular carcinoma, or bleeding esophageal varices)
  • Cohort 2: Patients who discontinued previous pegylated interferon plus ribavirin treatment due to reasons other than null response
  • History of cardiovascular or cerebrovascular disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Combination without RO5024048

    Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients

    Drug: danoprevir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin · Drug: ritonavir

  • Experimental
    Combination with RO5024048

    RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys \[peginterferon alfa-2a\] and ribavirin) in prior null responder patients

    Drug: RO5024048 · Drug: danoprevir · Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin · Drug: ritonavir

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: Incidence of adverse events

    Time frame: 48 weeks

  2. Pharmacokinetics (PK): Area under the concentration-time curve (AUC)

    Time frame: Intensive PK sample collection during initial 2 week dosing period, followed by routine sampling during treatment up to Week 24

  3. Antiviral activity: Hepatitis C virus (HCV) RNA levels assessed by Roche COBAS Taqman HCV Test

    Time frame: 48 weeks

Secondary outcomes

  1. Emergence of viral resistance: HCV RNA gene sequence variations

    Time frame: From baseline to Week 48

  2. Virologic response: HCV RNA levels

    Time frame: approximately 1 year

07

Study locations

27 sites
  • Birmingham, Alabama 35294, United States
  • Anaheim, California 92801, United States
  • Coronado, California 92118, United States
  • La Jolla, California 92037, United States
  • Long Beach, California 90807, United States
  • DeLand, Florida 32720, United States
  • Miami, Florida 33136, United States
  • Orlando, Florida 32803, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30309, United States
  • New Orleans, Louisiana 70112, United States
  • Detroit, Michigan 48202-2689, United States
  • Hillsborough, New Jersey 08844, United States
  • New York, New York 10021, United States
  • San Antonio, Texas 78215, United States
  • Fitzroy, South Australia 3065, Australia
  • Melbourne, Victoria 3124, Australia
  • Vancouver, British Columbia V6Z 2C7, Canada
  • Toronto, Ontario M5G 2C4, Canada
  • Montpellier, 34094, France
  • Auckland, 1142, New Zealand
  • Christchurch, 8140, New Zealand
  • Chorzów, 41-500, Poland
  • Myslowice, 41-400, Poland
  • Warszawa, 02-507, Poland
  • Wrocław, 51-149, Poland
  • Bratislava, 833 05, Slovakia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2011
First posted
Dec 1, 2011
Start
Apr 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results delay requested
Jul 20, 2016
Last update
Aug 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01483742
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 1, 2011
Start date
Apr 2012
Primary completion
Sep 2013
Completion
Sep 2013
Last update
Aug 1, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Danoprevir · Ritonavir

Start the discussion